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ABSTRACT
Introduction Focal therapy has emerged as a promising 
treatment option for men with localised prostate cancer. 
However, most of the evaluation of postoperative function 
has taken place at a relatively high, non- granular level. 
Most of the data we use to provide informed consent 
for our patients is obtained from retrospective series, or 
derived from prospective studies whose primary outcome 
was oncological. Finally, most studies have focused 
on erectile function and overlooked other, presumably 
important, elements of male sexual function. The present 
study aims at studying in- depth the sexual consequences 
of focal therapy with various energy sources.
Methods and analysis This will be a mixed- methods 
research study based on a retrospective and prospective 
cohort, recruited in parallel. The retrospective cohort 
will consist of patients treated with focal irreversible 
electroporation, and the prospective cohort of patients 
treated with three focal therapy energies. Participants will 
be recruited from two UK urology centres, one National 
Health Service and one private. On consent, patients 
will fill in self- administered validated questionnaires 
(International Index of Erectile Function-15 (IIEF-15), Male 
Sexual Health Questionnaire- Ejaculatory Dysfunction- Short 
Form (MSHQ- EjD- SF)) and semistructured interviews 
will be organised to collect patients’ expectations and 
postoperative changes in domains such as erection, 
ejaculation, orgasm, libido/sexual desire, masculinity/
virility, penile morphology, pain or discomfort, regret, 
shame, cancer- related stress, overall impact and partner 
satisfaction. An exploratory thematic analysis will be 
performed to detail recurring themes that will be grouped 
into clusters of experiences. We will then be able to find 
clusters of agreement and disagreement that will be 
illustrated using exemplar patient quotations.
Ethics and dissemination Ethical approval was obtained 
(Regional Ethics Committee reference 20/NW/0335), as 
well as Health Research Authority approval. Results will be 
published in open- access peer- reviewed journals. Findings 
will also be translated into patient information resources 
(leaflets, online information sheets).
Trial registration number ISRCTN11634296; Pre- results.
INTRODUCTION
Over the last decade, despite progress 
in surgical techniques (robotics) and 
perioperative management (medication), 
men’s ability to recover erectile function after 
radical prostatectomy has not improved. Over 
the last decade, the proportion of men who 
are able to recover erectile function within 24 
months after surgery has remained a constant 
30%.1 During this same period, progress in 
MRI of prostate cancer has enabled the emer-
gence of both image- guided biopsy and treat-
ments. This novel diagnostic and therapeutic 
pathway has conferred a step- change in like-
lihood that men will experience little, if any, 
deterioration in their genitourinary function 
as a result of their prostate cancer diagnosis 
and treatment.2
While the stability of men’s genitouri-
nary functional status through the process 
of treatment is something to be celebrated, 
most of the evaluation of function has taken 
place at a relatively high, non- granular level. 
Most of the data we use to provide informed 
consent for our patients is obtained from 
Strengths and limitations of this study
 ► This will be the first study using qualitative research 
methods to study in- depth sexual consequences of 
focal therapy using various energies to treat local-
ised prostate cancer.
 ► The design of the study, including both patients al-
ready treated at various postoperative time points, 
and patients enrolled prospectively and interviewed 
before and after treatment will allow for a unique 
perspective on patients’ expectations and the actual 
effects of focal therapy.
 ► The concomitant use of self- administered validated 
questionnaires will help position the study popula-
tion in regard to previously published quantitative 
studies.
 ► Study limitations include the relatively small sample 
size for quantitative outcomes, absence of base-
line evaluation for the retrospective cohort, and the 
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retrospective—usually single- centre—series, or derived 
from prospective studies whose primary outcome was 
oncological.3
Moreover, these studies have—to a very large extent—
focused exclusively on erectile function. Other, presum-
ably important, elements of male sexual function 
(orgasmic sensation, ejaculatory function, penile shape, 
climacturia) have been largely overlooked. There have 
been some notable exceptions, such as the careful 
morphometric analysis of penile length following high- 
intensity focused ultrasound and cryotherapy.4 However, 
we have hardly any insight into the detailed conse-
quences of some of the newer energy sources (such 
as irreversible electroporation) that are being used to 
treat the prostate in a tissue- selective manner.5 Quali-
tative research methods enable in- depth exploration 
of a predefined domain and have already been used 
to collect patients’ sexual recovery after whole- gland 
treatment.6
The present mixed- methods study will address this 
need by evaluating qualitative sexual outcomes after three 
different focal therapy modalities, to elicit the evolution 
of the sexual function of preoperatively potent patients in 
the early postoperative period (3 months) and at various 
postoperative time points ranging from 3 to 24 months.
METHODS AND ANALYSIS
Study design
This will be a mixed- methods research study based on a 
retrospective and a prospective cohort. Both cohorts will 
be recruited in parallel.
The retrospective cohort will consist of patients treated 
with focal irreversible electroporation, and the prospective 
cohort of patients treated with three focal therapy energies.
The retrospective arm of the study will allow us to obtain 
in- depth details of the evolution of the sexual function of 
patients at various time points up to 2 years after surgery. 
This cohort of patients will be able to provide perspective 
and be more likely to be relieved of the stress related to 
the oncological outcome. Since there will be a significant 
time gap between the event and the interview, we also 
decided to include patients prospectively, to ensure the 
collection of in- depth sexual patient’s experiences as they 
are being experienced.
Validated patient- reported outcomes questionnaires will 
allow for a further description of the study population and 
help position and compare the results obtained with other, 
mostly quantitative, studies. All steps of this study have been 
designed to be completed remotely.
An overview of the study design is shown in figure 1.
Study outcomes
Primary outcome measure
Qualitative sexual outcomes gathered using semistruc-
tured telephone interviews at 3 months after focal therapy 
(prospective cohort).
Secondary outcome measures
 ► Preoperative patients’ expectations assessed using 
semistructured telephone interviews before treatment 
(prospective cohort).
 ► Qualitative sexual outcomes gathered using semis-
tructured telephone interviews at various time points 
ranging from 6 months to 24 months after surgery 
(retrospective cohort).
 ► Erectile and ejaculatory function measured by Inter-
national Index of Erectile Function-15 (IIEF-15) 
and Male Sexual Health Questionnaire- Ejaculatory 
Dysfunction- Short Form (MSHQ- EjD- SF) at baseline 
and 3 months (prospective cohort).
 ► Erectile and ejaculatory function measured by IIEF-15 




Interviews will be conducted by the same interviewer 
(GF) using a predefined interview guide. The inter-
view guide will be defined for all semistructured inter-
views, with the input of the andrologist and qualitative 
researcher, part of the study team. Areas to be covered 
include changes to erections, ejaculation function and 
pleasure, orgasmic sensation, pain/discomfort, libido/
desire, sense of masculinity/virility, penile morphology 
(online supplemental material). We will also explore 
feelings of regret, shame, cancer or sexual related stress, 
impact on partners and any treatments taken/consid-
ered effective. On consent, follow- up phone calls will be 
performed if new themes arise from the first interviews 
and result in an amendment of the interview guide. 
Interviews will be recorded using dedicated hardware 
and transcribed.
Figure 1 Study overview (A) retrospective cohort; (B) 
prospective cohort)—no treatment allocation will be 
made and patients will be treated based on their treating 
physician’s choice, as part of standard care. IRE: irreversible 
electroporation; HIFU: high intensity focused ultrasound.
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Validated questionnaires
Two validated questionnaires, IIEF-15 and MSHQ- EjD- SF 
exploring sexual and ejaculatory function will be self- 
administered prior to the semistructured interviews. The 
IIEF-15 is a 15- question questionnaire exploring erectile 
function (questions 1–5 and 15), intercourse satisfaction 
(questions 6–8), orgasmic function (questions 9 and 10), 
sexual desire (questions 11 and 12) and overall satisfac-
tion (questions 13 and 14). Scores can be interpreted for 
each domain or as a whole, with a maximal score of 5 
for each question. It has been chosen because it is widely 
used and validated as a tool to evaluate the sexual conse-
quences of prostate cancer treatment and will allow for a 
comparison with other studies and treatment modalities. 
The MSHQ- EjD- SF focuses on the ejaculatory function 
and contains four questions also each rated on a 5- point 
scale evaluating the quality and volume of the ejaculate 
as well as the bother induced by a potential alteration in 
ejaculation. It has been chosen as the changes expected 
after focal therapy are likely to be modest and require a 
specific and precise tool to be accurately captured. Ques-
tionnaires will be delivered electronically or through the 
mail.
Sample size and sampling
The sample size was determined based on the review of 
the existing literature on qualitative research in prostate 
cancer6–8 and discussions with qualitative researchers.
Prospective cohort
The prospective cohort will be recruited using quota 
convenience sampling to allow for the exploration of 
sexual outcomes of patients treated using three focal 
energy modalities: high intensity focused ultrasound 
(HIFU), cryotherapy and irreversible electroporation. 
No treatment allocation will be made, and patients will 
be treated according to their treating physician’s choice, 
as part of standard care. Enrolment will be possible 
providing preoperative potency (erections sufficient for 
penetration), electronic consent and sufficient knowl-
edge of English to fill- in the self- administered question-
naires. We aim at recruiting 30 patients in total for the 
prospective cohort (10 patients for each treatment arm).
Retrospective cohort
Preoperatively potent patients treated with irreversible 
electroporation in the last 24 months will be sent an invi-
tation letter. We chose to focus on irreversible electropo-
ration as it is the most recently developed focal therapy 
energy with the least studied sexual consequences. On 
electronic consent returned by email, semistructured 
telephone interviews will be offered to describe qualita-
tive outcomes at agreed time points after surgery. The 
cohort will be selected purposely so as to represent a 
variety of postoperative time points (ranging between 3 
and 24 months). We aim at recruiting 20 patients for this 
retrospective cohort.
Study timeline and setting
The study is set to last for 6 months, with the recruit-
ment of both cohorts being led in parallel. Patients will 
be recruited from 2 UK urology centres, one National 
Health Service (University College London Hospital) and 
one private practice (London Urology Specialists).
Analysis plan
The interpretation and analysis of data from the qualita-
tive part of the study will be conducted by two members 
of the research team including a qualitative researcher, 
both manually and with the help of a designated soft-
ware (NVivo V.12). An exploratory thematic analysis will 
be performed to identify recurring themes that then will 
be grouped into clusters to describe the impact of these 
treatment experiences. We will then identify areas of 
agreement and disagreement that will be illustrated using 
patients’ words in quotations. Each transcript will be anal-
ysed separately by two researchers from the study team 
and any disagreement will be addressed by consulting 
with a third member of the team.
Research will be conducted and reported according 
to the Consolidated criteria for Reporting Qualitative 
research statement.9
Patient and public involvement
No patient was involved in the design of this study. A 
summary of findings written in lay language will be 
offered to all study participants.
Study status
Recruitment and data collection are expected to begin in 
November 2020. Completion of data collection and data 
analysis is expected to start in August 2021.
DISCUSSION
Sexual consequences of conventional prostate cancer 
treatments can impact significantly on men’s quality of 
life. A large survey study including 934 men treated for 
localised prostate cancer found that significant sexual 
function bother was reported by 39% of men and strongly 
associated with treatment decision regret.10 The quality of 
information we are able to provide patients regarding post-
operative outcomes has been shown of major importance 
to reduce treatment decision regret.11 An international 
multidisciplinary consensus recently concluded that func-
tional outcome assessment was a key component of focal 
therapy surveillance, but provided little guidance on how 
this endpoint should be achieved.12 The tools commonly 
used to evaluate patients’ post- treatment sexual func-
tion (self- administered validated questionnaires such as 
International Index of Erectile Function -5 (IIEF-5), IIEF-
15, Expanded Prostate cancer Index Composite (EPIC) 
scores) have been developed and validated in a popula-
tion of men treated with whole- gland treatments (surgery, 
radiotherapy), and provide a gross evaluation, focusing 
on erection and omitting other aspects such as orgasmic, 
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ejaculatory function, sexual desire or other masculinity/
virility issues. Although this might be sufficient to capture 
major changes expected after conventional, whole- gland 
treatments, these tools appear to lack depth in capturing 
more subtle changes after tissue- preserving treatment 
using focal therapy.
Our study will be, to our knowledge, the first study 
aiming at analysing in- depth the sexual consequences 
of focal therapy. The retrospective cohort will help to 
explore and define the most important components 
of impact on sexual function directly from men under-
going focal therapy. The prospective cohort approach 
will identify those domains with a greatest degree of nega-
tive impact on sexual function and performance. Impor-
tantly, the results will improve the information given to 
patients before treatment when decision making can be 
problematic and confusing.13 We hope that the depth of 
detail obtained here will help men to decide on treatment 
modality with a clear knowledge of the potential conse-
quences of each, particularly for those who consider the 
preservation of sexual function as a priority.
ETHICS AND DISSEMINATION
Ethical considerations
This study deals with a sensitive topic and interviews 
will be performed outside of standard- of- care clinical 
follow- up. Informed consent will be sought. Ethical 
approval was obtained (Regional Ethics Committee refer-
ence 20/NW/0335), as well as Health Research Authority 
approval.
Dissemination
We plan to communicate the results of this study through 
abstracts submitted to international conferences, and aim 
at publishing the results of each cohort in open- access 
peer- reviewed journals. Findings will also be translated 
into patient information resources (leaflets, online infor-
mation sheets).
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